Clinical Trial Update: A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing TAK-881 with HYQVIA in adults with chronic inflammatory demyelinating polyradiculoneuropathy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyradiculoneuropathy

Drugs mentioned

• HYQVIA (immunoglobulin G (IgG) with recombinant human hyaluronidase)
• TAK-881

Snippet

Sponsor: Takeda | Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Phase 3 | Status: RECRUITING